Acute coronary syndrome

All type of patients:  11 trials  - ATACS (Cohen) - Holdright - Cohen (ATACS pilot) (heparin+aspirin vs asp) - RISC (heparin+aspirin vs ASP) - Theroux (heparin+aspirin vs PBO) - Gurfinkel (UFH+aspririn vs aspirin) - Theroux (heparin vs PBO) - RISC (heparin vs PBO) - Cohen (ATACS pilot) (heparin vs asp) - Theroux (heparin+ASP vs ASP) - RISC (ASP+ heparin vs PBO)

UFH vs control (on top of aspirin)

No demonstrated result

UFH vs placebo

No demonstrated result

suggested recurrent angina by 63% (not demonstrated)

suggested myocardial infarction (fatal and non fatal) by 93% (not demonstrated)

UFH vs placebo (on top of aspirin)

No demonstrated result

Minor bleeding by 2090% (harmful effect)

UFH + aspirin vs placebo

No demonstrated result

suggested myocardial infarction or death by 81% (not demonstrated)

suggested recurrent angina by 53% (not demonstrated)

suggested myocardial infarction (fatal and non fatal) by 86% (not demonstrated)

UFH, warfarin vs aspirin

No demonstrated result

UFH, warfarin vs control (on top of aspirin)

No demonstrated result

Acute myocardial infarction

All type of patients:  4 trials  - ISIS-2 Pilot - ECSG - OSIRIS - DUCCS

UFH vs no heparin

No demonstrated result

UFH vs placebo

No demonstrated result

See more clinical conditions

Patients eligible to receive fibrinolytic therapy:  2 trials  - ECSG - DUCCS

UFH vs no heparin

No demonstrated result

UFH vs placebo

No demonstrated result

Peripheral vascular diseases

All type of patients:  2 trials  - Antonicelli - Tesi

HNF vs placebo

No demonstrated result

Superficial thrombophlebitis

Superficial thrombophlebitis of the leg :  1 trials  - Belcaro (prophylactic UFH vs no)

Prophylactic UFH vs no treatment

No demonstrated result

Thrombosis prevention

All type of patients:  7 trials  - Wille-Jorgensen - Wille-Jorgensen - *Rasmussen (adj) - Siragusa (H) - Killewich - Ramos - Torngren

GCS + UFH vs UFH

No demonstrated result

suggested Deep vein thrombosis by 49% (not demonstrated)

IPC + UFH vs control

No demonstrated result

IPC + UFH vs UFH

No demonstrated result

suggested pulmonary embolism (symptomatic and asymptomatic) by 58% (not demonstrated)

See more clinical conditions

All type of surgery:  75 trials  - Williams - Abraham-Inpijn - Lowe - Morris - Welin-Berger - Bergqvist - Hampson - Moskovitz - Gallus - VTCSG - Mannucci - Dechavanne - Dechavanne - Lahnborg - Xabregas - Bergqvist - Galasko - Moskovitz - Svend-Hansen - Gallus - Morris - Kakkar (IMT) - Gruber - Kakkar - Kiil - Torngren - Torngren - Lahnborg - Lahnborg - Covey - Belch - Taberner - Strand - Roberts - Ribaudo - Wu - Lawrence - Muiticentre - Muiticentre 53,S4 - Muiticentre - Jourdan - van Geloven - Loew - Vinazzer - Gordon-Smith - Nicolaides - Multiunit - Abernethy - Clarke-Pearson - Plante - Abraham-Inpijn - Spebar - Sagar - Koppenhagen - Bergqvist - Torngren - Kruse-Blinkenberg - Kraytman - Marchetti - Gallus - Gallus - Groote Schuur - Kraytman - Kraytman - Kettunen - Caloghera - Marchelli - Ziemski - Bejjani - Coe - Sebeseri - Allen - Hedlund - Kutnowski - Vandendris

UFH vs aspirin

No demonstrated result

UFH vs DHE

No demonstrated result

UFH vs no treatment

No demonstrated result

suggested Deep vein thrombosis by 57% (not demonstrated)

suggested Bleeding by 57% (not demonstrated)

UFH vs oral anticoagulant

No demonstrated result

suggested Deep vein thrombosis by 72% (not demonstrated)

UFH vs placebo

No demonstrated result

suggested Deep vein thrombosis by 56% (not demonstrated)

General non orthopaedic surgery:  3 trials  - Wille-Jorgensen - Wille-Jorgensen - *Rasmussen (adj)

GCS + UFH vs UFH

No demonstrated result

General surgery:  47 trials  - Kakkar (IMT) - Gruber - Kakkar - Kiil - Torngren - Torngren - Lahnborg - Lahnborg - Covey - Belch - Taberner - Strand - Roberts - Ribaudo - Wu - Lawrence - Muiticentre - Muiticentre 53,S4 - Muiticentre - Jourdan - van Geloven - Loew - Vinazzer - Gordon-Smith - Nicolaides - Multiunit - Abernethy - Clarke-Pearson - Plante - Abraham-Inpijn - Spebar - Sagar - Koppenhagen - Bergqvist - Torngren - Kruse-Blinkenberg - Kraytman - Marchetti - Gallus - Gallus - Groote Schuur - Kraytman - Kraytman - Kettunen - Caloghera - Marchelli - Ziemski

UFH vs aspirin

No demonstrated result

UFH vs DHE

No demonstrated result

UFH vs no treatment

No demonstrated result

suggested Deep vein thrombosis by 59% (not demonstrated)

suggested non-fatal pulmonary embolism by 41% (not demonstrated)

suggested Bleeding by 56% (not demonstrated)

UFH vs oral anticoagulant

No demonstrated result

suggested Deep vein thrombosis by 72% (not demonstrated)

UFH vs placebo

No demonstrated result

suggested Deep vein thrombosis by 58% (not demonstrated)

Medical patients:  3 trials  - Blech - Cade - Gardlund

UFH vs control

No demonstrated result

suggested fatal pulmonary embolism by 74% (not demonstrated)

Neurosurgery:  1 trials  - Cerrato

UFH vs no treatment

No demonstrated result

suggested asymptomatic DVT by 82% (not demonstrated)

Orthopedic surgery:  21 trials  - Williams - Abraham-Inpijn - Lowe - Morris - Welin-Berger - Bergqvist - Hampson - Moskovitz - VTCSG - Mannucci - Dechavanne - Dechavanne - Lahnborg - Xabregas - Bergqvist - Galasko - Moskovitz - Svend-Hansen - Gallus - Morris - Manganelli

out of hospital UFH vs standard prophylaxis

No demonstrated result

UFH vs no treatment

No demonstrated result

suggested Deep vein thrombosis by 52% (not demonstrated)

UFH vs placebo

No demonstrated result

suggested Deep vein thrombosis by 48% (not demonstrated)

Patients with myocardial infarction:  7 trials  - Handley (low dose) - Handley - Gallus - Emerson - Zawilska - Warlow - Pitt

UFH vs control

No demonstrated result

suggested Deep vein thrombosis by 84% (not demonstrated)

UFH vs placebo

No demonstrated result

Urologic surgery:  7 trials  - Bejjani - Coe - Sebeseri - Allen - Hedlund - Kutnowski - Vandendris

UFH vs no treatment

No demonstrated result

UFH vs placebo

No demonstrated result

suggested Deep vein thrombosis by 76% (not demonstrated)